节点文献

止血组方对脾虚型功能失调性子宫出血的疗效研究

Observation on Curative Effect of Hemostasis Combination Prescription on Spleen Deficiency Dysfunctional Uterine Bleeding

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 吴雅楠郭海云刘亚宁王皓吕梅张勇

【Author】 WU Ya’nan;GUO Haiyun;LIU Ya’ning;North China Petroleum Bureau General Hospital;

【通讯作者】 吴雅楠;

【机构】 华北石油管理局总医院

【摘要】 目的:观察止血组方对于脾虚型功能失调性子宫出血的临床疗效。方法:选取2016年7月-2017年6月来本院门诊就医的105例脾虚型功能失调性子宫出血患者,按照不同治疗方法将患者分为治疗组(n=52)和对照组(n=53)。治疗组采用脾虚型止血组方系列治疗,对照组采用口服妈富隆治疗,治疗3个月经周期后观察6个月,观察治疗前、治疗1个月经周期、治疗3个月经周期、停药3个月、停药6个月的月经相关情况,并进行统计分析。结果:治疗组的止血时间为(8.13±2.05)d较对照组的(5.30±1.75)d明显偏长(P<0.01),但治疗组痊愈率为73.1%,明显高于对照组的47.2%(P<0.01);且停药6个月后,治疗组经期为(6.75±1.85)d,短于对照组的(8.21±2.69)d(P<0.01);治疗组子宫内膜厚度为(0.51±0.06)cm,优于对照组的(0.61±0.11)cm(P<0.01);治疗组的血红蛋白含量为(121.31±5.78)g/L,优于对照组的(116.34±9.63)g/L(P<0.01)。结论:脾虚型止血组方更利于脾虚型功能失调性子宫出血的控制与稳定。

【Abstract】 Objective:To observe the clinical effect of hemostasis combination prescription on spleen deficiency dysfunctional uterine bleeding(DUB).Method:105 patients with dysfunctional uterine bleeding due to spleen deficiency who came to the outpatient department of our hospital from July 2016 to June 2017 were selected,they were divided into treatment group(n=52)and control group(n=53)according to different treatment methods.The treatment group was treated with a series of hemostasis prescription,the control group was treated with Marvelon.After treatment for 3 menstrual cycles,observation for 6 months,before treatment,1 menstrual cycle,3 menstrual cycles,3 months of drug withdrawal,and 6 months of drug withdrawal were observed and statistically analyzed.Result:The time of hemostasis in the treatment group was(8.13±2.05)d,significantly longer than(5.30±1.75)d of the control group(P<0.01).The cure rate of the treatment group was 73.1%,significantly higher than 47.2% of the control group(P<0.01).After stopping the medicine for 6 months,the menstrual cycle of the treatment group was(6.75±1.85)d obviously superior to(8.21±2.69)d in the control group(P<0.01);the endometrial thickness of the treatment group was(0.51±0.06)cm,obviously superior to(0.61±0.11)cm in the control group(P<0.01);and the hemoglobin content of the treatment group was(121.31±5.78)g/L,obviously superior to(116.34±9.63)g/L in the control group(P<0.01).Conclusion:The spleen deficiency type hemostasis combination prescription is more conducive to the control and stability of the spleen deficiency DUB.

【基金】 中国石油华北油田科技项目(2017-HB-G0903)
  • 【文献出处】 中国医学创新 ,Medical Innovation of China , 编辑部邮箱 ,2019年05期
  • 【分类号】R271.9
  • 【被引频次】1
  • 【下载频次】27
节点文献中: 

本文链接的文献网络图示:

本文的引文网络